health biotech news today obesity drugs glp-1 Market Overview: Agonists and the Market | Blog GLP-1 Market Expected to More
Description
Four of the articles reviewed showed that there was increased incidence of aspiration among GLP-1 RA users (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)
Sommer, Genve (Mdecine de famille)
Some patients who tolerate once-weekly injectable GLP-1s may find daily oral GI exposure more difficult, or vice versa
Theyre ushering in a new standard of care and a renewed push towards innovation in metabolic conditions and beyond
54 19 | DOI : 10.1016/j.peptides.2013.12.015 Y
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimers and Parkinsons Diseases
